Lantheus Holdings(US:LNTH) Globenewswireยท2025-09-29 17:15Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [3][4][5]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases globally, with Pylarify being a significant product in its portfolio [2]. Allegations of Misrepresentation - The lawsuit claims that Lantheus's executives created a false impression of the company's revenue projections and growth while downplaying risks from competition and market dynamics [3]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to a lack of accurate understanding of pricing and competitive dynamics [3]. Financial Performance and Stock Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, attributing it to a "temporal competitive disruption," and subsequently lowered its full-year growth projections from low-single-digit to mid-single-digit growth to flat-to-low single-digit growth [4]. - Following this announcement, Lantheus's stock price fell by more than 23% [4]. - On August 6, 2025, the company announced further disappointing results, with Pylarify sales down 8.3% year-over-year, leading to a nearly 29% drop in stock price after slashing fiscal year 2025 growth projections [5]. Legal Process for Lead Plaintiff - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Lantheus securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6].